Friday, December 09, 2016 11:22:15 AM
I think the anti-pd-1 non-responder approach is in fact a great way for the company to garner some much-needed attention. Truly, what options do metastic melanoma patients have if they fail anti-pd-1 monotherapy, currently the gold standard for this indication?
I am encouraged by what I have seen so far with their melanoma results. The response durations and level of responses, i.e. complete responders, suggests to me that the treatment is definitely priming patients for checkpoint inhibitor use and they are essentially creating clinically effective in-situ vaccines as demonstrated by response durations. You simply do not see these types of responses in monotherapy anti-pd-1 data. And, you don't see as many complete responses even in combination treatments among all-comers.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM